A common mutation comes into play for PRMT5 inhibition.

Tolerability could decide first-line therapy in EGFRm disease.

Early data with IDE849 look better those with Zai’s zocilurtatug pelitecan.

Investors now have more reasons to doubt Harmoni's ability to back US approval.

The EGFR x HER3 ADC iza-bren looks good, but still has much to prove.

Posters and mini-orals include another VEGF bispecific.

Summit and Nuvalent have scored prized plenary spots.

Sunmo succeeds in a setting very similar to Starglo's.

The company sees an improvement with a Tecvayli/Talvey combo vs either monotherapy.

The Enliven molecule looks competitive against Scemblix, triggering a $200m raise.